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ABSTRACT The Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria for
chronic obstructive pulmonary disease (COPD) use a fixed threshold of forced expiratory volume in 1 s
(FEV1)/forced vital capacity (FVC) ratio (<0.70) in post-bronchodilation spirometry to indicate disease,
which has been shown to underestimate and overestimate disease prevalence in younger and older adults,
respectively, whilst criteria based on reference values have better accuracy. Differences in reference values
have limited their use in international studies. However, the new Global Lung Function Initiative reference
values (GLI2012) showed FEV1/FVC to be the least dependent on ethnicity. The aim of this study was to
assess the prevalence of airflow limitation with GLI2012 and the degree of underdetection or
overestimation related to the use of GOLD in the general population.
A Finnish population sample of 1323 subjects (45% male) with post-bronchodilation spirometry was
studied.
80 subjects (6.0%) and 55 subjects (4.2%) were identified with airflow limitation with GOLD and
GLI2012 criteria, respectively. The proportion of overestimation with GOLD increased with age from 25%
of cases in 50-year-olds to 54% in 70-year-olds. Using z-score-based grading resulted in more dispersion
in severity grading.
In conclusion, the GOLD criteria cause a marked overestimation already from 50-year-olds and should
be replaced with the GLI2012 criteria to improve diagnostic accuracy.
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Introduction
In the early 1990s, chronic obstructive bronchitis was poorly understood, mostly under-recognised and
with limited research focus. In the late 1990s, the international recognition of the need to improve
diagnostics and research in the disease spectrum then coined with the name chronic obstructive
pulmonary disease (COPD) led to the formation of the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) framework with a major effort aiming for earlier recognition and improved research
understanding of this condition [1]. Until then, the main focus of national and international efforts in
obstructive airways diseases had been in asthma.
The GOLD framework set forth to improve earlier diagnostics by making diagnostic criteria easily
accessible and understandable. Whilst it was already understood that criteria for airflow limitation are
dependent on sex, height and age (and also to some extent ethnicity), the GOLD guidelines introduced a
simplified “rule of thumb” of the so-called fixed-limit criterion of forced expiratory volume in 1 s (FEV1)/
forced vital capacity (FVC) <0.70 in post-bronchodilation spirometry indicating airflow limitation in order
to make the diagnosis easier [1]. Reference values vary from one population to another and criteria based
on reference values were seen to introduce bias into research efforts. As population reference values vary
greatly both in models and lower limits of normal (LLNs), their use was considered difficult to advocate
and distribute internationally [1].
There is a large body of knowledge that criteria based on reference values are superior to fixed-limit
criteria in the diagnosis of airflow limitation consistent with COPD [2–9]. Selected population studies
highlighting the differences found between criteria based on fixed limits and reference values are
summarised in table 1. In addition to the differences between the reference values used and their
representativeness in the study population, the extent of difference of prevalence estimates is affected by
age and sex distribution and the prevalence of smoking in the study population. COPD is a
multicomponent disease and the use of a simplified criterion of a fixed limit of FEV1/FVC poses a risk of
excessive simplification of a clinical entity that is necessarily complex [31]. In a recent review of the
clinical relevance between these two criteria, the conclusion was that when these two criteria were in
disagreement, an alternative diagnosis should be considered, particularly among older individuals with less
severe airflow limitation where the criteria based on reference values performed better [32]. Even the
GOLD guidelines included a recommendation in the 2011 revision that criteria relative to reference values
should be considered in the elderly, as the fixed-limit criterion causes overdiagnosis in ageing populations
[33]. However, it did not specify what age should be considered “old”. In the 2015 update, the GOLD
guidelines already recommend the use of reference values whenever available; however, the main
document still endorses the fixed-limit criterion as the main diagnostic criterion [34].
Until recently the problem of a lack of uniform reference values has invalidated comparisons between
populations and different geographical areas. In 2012, the European Respiratory Society Global Lung
Function Initiative introduced the first global reference values for spirometry with the GLI2012 reference
equations [10]. These all-age reference values provide models for different ethnic backgrounds using the
generalised additive model for location, scale and shape (GAMLSS) model [23, 35]. The method
summarises the changing distribution by three curves representing the median (M), coefficient of variation
(S) and skewness, the latter expressed as after a Box–Cox power λ (L) transformation [23, 35]. The FEV1/
FVC ratio was found to be the least dependent on ethnicity of all evaluated spirometry variables [10].
Although the validity of the global reference equations has been evaluated in only very few
population-based samples, these reference values provide for the first time a uniform model that depicts
decline of lung function with age, sex and height, and enable the use of LLN criteria for epidemiology and
research between different populations [10, 36]. The GLI2012 reference values have been endorsed by all
major international respiratory societies [10]. In a recent study among very old adults (⩾80 years old)
from Belgium, only airflow limitation defined by GLI2012 was independently associated with mortality,
whereas subjects fulfilling the GOLD criterion without reduced FEV1/FVC <LLN had no significantly
higher risk of mortality or hospitalisation [30].
The aim of our study was to assess the prevalence of airflow limitation with GLI2012, and the degree of
underdetection and overestimation of airflow limitation suggestive of COPD related to the use of the
GOLD criterion of a fixed limit of FEV1/FVC <0.70 in post-bronchodilation spirometry in the general
population. In addition, we aimed to evaluate the GOLD grading of airflow limitation compared with the
z-score-based grading of distribution of severity of impairment.
Materials and methods
We used data from the two Finnish centres participating in the FinEsS studies in respiratory epidemiology.
The study population was randomly sampled from the National Population Registry in 10-year age cohorts
and represents adults aged 20–75 years old. The study protocol has been described in detail previously
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TABLE 1 General population studies comparing the diagnostic criteria of forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.70 and
FEV1/FVC < lower limit of normal (LLN)
Study Country Subjects
(% male#)
Age group
years
Nonsmoker FEV1/FVC <0.70 FEV1/FVC <LLN Comment
Male Female Male Female
Present study Finland 1323 (45.0) 21–74 43.2 9.4 3.3 6.0 2.6 LLN fifth percentile GLI2012 [10]. Age-dependent
increase in difference between fixed limit and
LLN from 0.3% (40–49 years) to 10.6%
(70–74 years).
CELLI et al., 2003 [11] USA 9838 (47.8) 30–80 43.8 19.9 13.8 15.0 13.5 LLN fifth percentile NHANES [12]. Age-dependent
increase in difference between fixed limit
and LLN from −2.1% (40–44 years) to 28.8%
in (70–74 years).
HANSEN et al., 2007 [4] USA 9403¶ (42.9) 20–80 62.6¶ 12.5¶ 8.2¶ 11.4¶ 9.4¶ LLN fifth percentile NHANES [12]. Age-dependent
increase in difference between fixed limit and
LLN from −3.1% and −4.4% (40–49 years) to
19.9% and 12.1% (>80 years) in men and
women, respectively.
VANFLETEREN et al., 2012 [13] The Netherlands 592 (50.7) 40–⩾70 34.4 28.5 19.5 19.7 17.8 LLN fifth percentile NHANES [12].
SCHOLES et al., 2014 [14] England and
Wales
7879 (42.3) 40–95 52.5 26.3 18.6 15.0 11.3 LLN fifth percentile GLI2012 [10]. The gap in
prevalence between GOLD and LLN increased in
older age groups. Sex differences in the risk of
obstruction were significantly higher in men
using GOLD compared with no significant
difference using LLN.
HNIZDO et al., 2006 [15] USA 13 842 20–80 NA 21.1 18.5 LLN fifth percentile NHANES [12]. Fixed-limit
criterion underestimates airflow obstruction by
29% in 20–49-year-olds and overestimates it by
58% in 50–80-year-olds when compared with
FEV1/FVC <LLN and FEV1 <100% predicted.
MANNINO et al., 2007 [16] USA 4965 (43.4) ⩾65 45.9 42.1 19.3 LLN fifth percentile NHANES [12]. Follow-up of
11 years found subjects with FEV1/FVC <0.70 but
>LLN to have increased mortality and
COPD-related hospitalisations.
PEREZ-PADILLA et al., 2007 [17] Latin America 5183 ⩾40 NA 21.7 11.7 Evaluated data with LLN fifth percentile NHANES
[12] and reference values derived from the same
study. Data evaluated in groups of high and low
risk of COPD based on smoking exposure.
Age-dependent increase in prevalence
in both groups.
SHIRTCLIFFE et al., 2007 [18] New Zealand 749 (54.2) 25–⩾70 46.2 14.2 9.0 LLN calculated from a concurrent study sample
of healthy nonsmokers. Age-adjusted
prevalences shown.
ROCHE et al., 2008+ [19] France 4764 (48.0) 45–⩾75 48.2 8.7 6.4 LLN fifth percentile European Coalition for
Steel and Coal [20].
Continued
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TABLE 1 Continued
Study Country Subjects
(% male#)
Age group
years
Nonsmoker FEV1/FVC <0.70 FEV1/FVC <LLN Comment
Male Female Male Female
SWANNEY et al., 2008 [7] The Netherlands 4557 Dutch 17–⩾90 NA 20.5 12.3 LLN from Dutch reference values from that
substudy, for UK data LLN of FALASCHETTI et al. [21]
and for USA the fifth percentile LLN of NHANES
[12]. GOLD guidelines caused false-positive
rates of up to 60% when applied to
entire populations.
UK 24 604 UK 13.4 14.1
USA 6829 USA 21.8 15.5
VAZ FRAGOSO et al., 2010 [22] USA 3502 (47.8) 40–80 40.8 27.0 13.8 LLN based on LMS method LLN fifth percentile
from study sample [23].
GARCIA-RIO et al., 2011 [24] Spain 3802§ 40–80 27.6§ 10.2 5.5 LLN based on ROCA et al. [25]. A subsample of 885
subjects (58.2% male) was further evaluated with
subjects diagnosed with GOLD but normal with
LLN presenting worse self-reported quality of life,
but similar exercise, frequency of exacerbations
and indices of systemic effects.
LAMPRECHT et al., 2011 [26] Austria 1258 (54.5) ⩾40 43.1 24.2 15.3 LLN fifth percentile NHANES [12]. Discordance
increased with age. Discordant cases more often
older, male and never-smokers, and had fewer
respiratory symptoms and better FEV1. Discordant
cases had heart disease significantly more often.
WAKED et al., 2011 [27] Lebanon 2201 (48.4) ⩾40 33.3 9.7 12.5 LLN based on LMS method fifth percentile from
study sample [23]. The number of never-smokers
was small and the LLN-based definition showed a
parabolic prevalence estimation by age.
DANIELSSON et al., 2012 [28] Sweden 548 (48.2) ⩾40 42.7 15.7 9.3 LLN fifth percentile NHANES [12].
VAN DIJK et al., 2015 [29] Canada 4882 (43.0) 40–⩾80 43.0 17.0 11.2 LLN fifth percentile NHANES [12]. Evaluated the
clinical significance of fixed-ratio- versus
LLN-based criteria. Fixed ratio alone may lead to
misdiagnosis. FEV1/FVC <LLN and a low FEV1 is
strongly associated with clinical outcomes.
Guidelines should be reconsidered to require
both spirometric abnormalities to reduce
overdiagnosis of COPD.
TURKESHI et al., 2015 [30] Belgium 411 (37.0) ⩾80 69.6 27.0 9.2 LLN fifth percentile GLI2012 [10]. Only airflow
limitation by GLI2012 was independently
associated with mortality. Subjects with FEV1/FVC
<0.70 but above GLI2012 LLN had no significantly
higher risk of mortality or hospitalisation.
Data are presented as n or %, unless otherwise stated. GLI2012: Global Lung Function Initiative reference values; NHANES: National Health and Nutrition Examination Survey; GOLD:
Global Initiative for Chronic Obstructive Lung Disease; COPD: chronic obstructive pulmonary disease; NA: not available. #: where available; ¶: includes only never-smokers and current
smokers from the population sample; +: primary care sample of routine preventive visits; §: full sample, study analysis of health-related quality of life pertaining to a smaller subsample
of subjects with no COPD.
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[37–39]. The study has been approved by the Helsinki University Central Hospital Board of Ethics
(Helsinki, Finland) and Länsi-Pohja Hospital Board of Ethics (Kemi, Finland).
628 adults (41.4% male) and 695 adults (48.3% male) participated in the clinical study in Helsinki and
Kemi, respectively, between 1998 and 2003, including post-bronchodilation spirometry fulfilling predefined
quality criteria. All participants were of Caucasian ethnic origin. Smoking history was evaluated by an
interview questionnaire administered by a nurse and subjects were categorised as nonsmokers, ex-smokers
or current smokers. All subjects having smoked any amount of cigarettes, cigars or pipe tobacco during
the previous year were classified as current smokers. Ever-smokers were all current smokers and former
smokers. Former smokers were required to have quit smoking at least 1 year previously, but to have
smoked at least one cigarette per day for 1 year previously. In Kemi, a nonresponder study was conducted
in which younger smoking males were found to be less likely to participate in the survey. However, this
did not affect the study results significantly [39].
Airflow limitation in the lower airways was defined in this study by spirometry. Spirometry was completed
following American Thoracic Society criteria [40] with bronchodilation testing using 400 µg salbutamol
aerosol in two 200 µg doses using a spacer (Ventoline Evohaler with Volumatic; GlaxoSmithKline,
Brentford, UK). Only post-bronchodilation values of FVC, FEV1 and the FEV1/FVC ratio after
bronchodilation were analysed and reported. The descriptive statistics of the study sample are outlined in
table 2. The prevalence of smoking in different age categories in this study was at a similar level to other
population studies of the time (e.g. the Health 2000 study [41]), thus the sample would seem to be
representative of the general population also in terms of exposure levels.
GLI2012 reference values for Caucasians indicated airflow limitation if the FEV1/FVC ratio in the
post-bronchodilation spirometry was below the defined fifth percentile LLN of z-score −1.645 [10]. GOLD
criteria define airflow limitation as post-bronchodilation FEV1/FVC <0.70 [34]. A true-positive case of
airflow limitation consistent with COPD was defined as a case with FEV1/FVC <LLN and FEV1/FVC
<0.70, a false-negative case was defined as a case with FEV1/FVC <LLN but FEV1/FVC ⩾0.70 and a
false-positive case was defined as a case with FEV1/FVC ⩾LLN but FEV1/FVC <0.70. The false-positive
rate is the number of false-positive cases per study sample expressed as a percentage. The proportion of
false-positive cases of all cases identified using the GOLD criterion is false positives divided by the sum of
true positives and false positives.
The grading of degree of severity of airflow limitation was evaluated with the decreased ventilatory
capacity, i.e. lowered FEV1 relative to FEV1 % pred with the GLI2012 reference value as suggested by the
GOLD guidelines and relative to the individually calculated z-score as suggested by QUANJER et al. [10, 42].
In the GOLD recommendation, values of FEV1 % pred ⩾80 were considered mild COPD, 50–79 as
moderate COPD, 30–49 as moderately severe COPD and <30 as severe COPD [34]. In the z-score-based
TABLE 2 Characteristics of the study population
Male Female
Subjects 596 727
Age years 48.8±13.2 48.2±13.0
Height cm 176.5±6.6 163.0±6.1
BMI kg·m−2 26.4±3.9 25.9±4.9
FEV1 L 3.9±0.9 2.9±0.6
FVC L 4.9±0.9 3.5±0.6
FEV1/FVC 0.796±0.082 0.822±0.063
FEV1 z-score GLI2012 [10] 0.04±1.07 0.11±0.94
FVC z-score GLI2012 [10] −0.02±0.90 −0.03±0.84
FEV1/FVC z-score GLI2012 [10] 0.09±1.07 0.19±0.86
Smoking status
Nonsmoker 31.4 52.8
Ex-smoker 36.4 22.3
Current smoker 32.2 24.9
Physician-diagnosed asthma 6.4 7.0
Physician-diagnosed COPD 2.9 2.8
Data are presented as n, mean±SD or %. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC:
forced vital capacity; GLI2012: Global Lung Function Initiative reference values; COPD: chronic obstructive
pulmonary disease.
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assessment of FEV1, individual z-score values >−2 were considered mild, between −2 and −2.5 as
moderate, between −2.5 and −3 as moderately severe, between −3 and −4 as severe, and <−4 as very
severe impairment of the ventilatory capacity [42].
The GLI2012 predicted values and z-scores for each study participant were calculated using R (version
2.15.1; www.cran-R.org) with the macro provided by the Global Lung Function Initiative [43]; all other
analyses were conducted using SPSS Statistics for Macintosh version 22.0 (IBM, Armonk, NY, USA). The
Chi-squared test was used to compare groups and the Mantel–Haenszel Chi-squared test was used for
trends. A p-value of 0.05 was considered significant in all analyses.
Results
The distribution of post-bronchodilation FEV1/FVC relative to GLI2012 reference values versus the
absolute FEV1/FVC ratio is shown in figure 1. The GOLD criteria identified overall 6.0% of subjects with
airflow limitation; 9.4% of males and 3.3% of females (p<0.001). Correspondingly, the GLI2012 criteria
identified 4.2% of subjects with airflow limitation; 6.0% and 2.6% of males and females, respectively
(p=0.002). Among subjects with airflow limitation identified by GOLD, 39.3% of cases were false positive
in males and 25.0% of cases were false positive in females (p=0.12). The rate of false positives increases
with age in both males and females, as shown in figure 2. The rate of false positives increases slightly but
not significantly with height: 1.4% for subjects <160 cm, 2.2% for subjects 160–179 cm and 2.5% for
subjects ⩾180 cm (p=0.713). Of the false-positive subjects (n=28), taller subjects had higher mean z-scores
for FEV1/FVC for subjects <160 (–1.57, 95% CI −1.79–−1.35), 160–179 (−1.26, 95% CI −1.39–−1.14)
and >180 cm (−1.13, 95% CI −1.36–−0.90), as shown in figure 3. The proportion of false positives of all
detected cases was 45.8% in subjects ⩾60 years of age (table 3), but false positives were found already in
subjects aged 40–49 years. However, the numbers of cases in the younger age categories were limited.
As the GOLD criteria are prone to overdiagnosis of older subjects with normal FEV1/FVC based on LLN of
reference values, the excess cases are found mostly in the mild category with normal FEV1, as shown in table 4.
These subjects have both normal FEV1/FVC and FEV1 based on LLN of reference values. In the moderate to
severe categories, the population prevalences are thus equal. Use of simplified percentage of predicted criteria
(GOLD grading) failed to identify the individual variation in the LLN in the older age groups and thus more
subjects end up in the moderate COPD category. Figure 4 illustrates the relationship between FEV1 % pred
GLI2012 and the individually calculated FEV1 z-score in the whole population sample. Using 80% of predicted
overidentifies reduced ventilatory capacity at the population level in 45 subjects (3.4%).
Discussion
The GOLD criteria were originally introduced to improve diagnostics to facilitate earlier identification of
subjects with COPD [1]. However, the criteria are known to overdiagnose older individuals [2, 3, 7, 18, 22].
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The use of more accurate criteria based on reference values has been limited by the variability of local
reference values and the lack of a uniform definition of abnormal. The GLI2012 reference values provide a
uniform definition for LLN for the first time [10]. We show that in a population-based sample in Finland
the spirometric GOLD criteria overestimate COPD prevalence by 35% and up to 54% of cases in the oldest
age category of ⩾70 years. Overdiagnosis starts already at age 50–59 years where subjects with normal
spirometry on LLN criteria would be diagnosed with airflow limitation consistent with COPD according to
the GOLD criteria.
Clinical relevance of diagnostic criterion for airflow limitation
COPD is not a single disease but encompasses different diseases with varying prognosis [34]. It indicates a
functional disorder characterised by a chronic and progressive reduction in maximum expiratory flow
without clarifying the underlying mechanism [23]. There is no doubt that any diagnostic limit will have its
limitations as well. Reduced FEV1/FVC is not a dichotomous variable, but instead a continuum of values
including elevated, normal, borderline and significantly reduced values. MANNINO et al. [16] have shown
that subjects ⩾65 years of age with FEV1/FVC <0.70 but above their LLN were at an increased risk of
death or COPD-related hospitalisation during an 11-year follow-up. The results were, however, contested
after publication, with the rate of diagnosis and events labelled as COPD-related hospitalisations having
been overly inclusive [44, 45]. In a recent review by VAN DIJK et al. [32] evaluating the clinical significance
of both criteria, the criteria based on reference values worked better in elderly subjects where discordant
cases should be further evaluated for other diagnoses. The FEV1/FVC ratio is directly associated with
FEV1, which has been shown to be one of the strongest predictors of all-cause morbidity and mortality
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even in the absence of lung disease [46–49]. Subjects with a low but still normal FEV1/FVC ratio might be
less healthy, and they do have lower lung function than their age and gender peers with higher FEV1/FVC
ratio and normal FEV1, but this does not imply causality with the diagnostic criteria for COPD. A reduced
FEV1/FVC ratio should be understood as a signal, but the diagnosis of COPD should be limited to truly
abnormal values. The use of assessment based on reference values also facilitates better understanding of
the grey areas around diagnostic criteria, i.e. a continuum of values around the LLN could improve the
understanding of general practitioners of patients at risk. The predicted FEV1/FVC ratio is also an estimate
with an associated degree of prediction error. Transition to the use of z-scores instead of percentage of
predicted with the implementation of the GLI2012 reference values will improve the accuracy of the LLN
especially in the elderly. Further research is needed to identify the significance of borderline categories of
z-score combined with exposure and symptoms to possibly facilitate earlier identification of subjects at
increased risk in primary care. However, airflow limitation is just one of the functional components of
COPD. The addition of FEV1 % pred and ratio of residual volume to total lung capacity has been found to
improve the identification of clinically relevant COPD [50].
Potential effect of height on degree of overdiagnosis of airflow limitation
The continued use of FEV1/FVC fixed-limit criterion by GOLD guidelines has been advocated with
similarities with the fixed limits agreed upon for other physiological measures such as elevated blood pressure
[31]. There are, however, fundamental physiological differences in these variables. One of the most evident is
TABLE 3 True-positive, false-negative and false-positive rates in age decades stratified by sex in the study population (n=1323)
Age years Male Female
True-positive
rate
False-negative
rate
False-positive
rate
Proportion
of cases
false
positive#
True-positive
rate
False-negative
rate
False-positive
rate
Proportion
of cases
false
positive#
<30 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0
30–39 3.3 0.8 0.0 0.0 0.0 0.7 0.0 0.0
40–49 2.0 0.0 0.7 25.0 2.4 0.0 0.0 0.0
50–59 5.2 0.0 3.0 36.4 4.5 0.0 0.6 11.1
60–69 15.7 0.0 11.1 41.4 2.3 0.0 2.3 50.0
⩾70 9.1 0.0 15.2 62.5 9.1 0.0 6.1 40.0
All 5.7 0.3 3.7 39.3 2.5 0.1 0.8 25.0
Data are presented as %. #: false positive/(true positive+false positive).
TABLE 4 Grading of degrees of airflow limitation in the study population (n=1323) according to
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [34] and to QUANJER et al. [42]
in subjects with lower limit of normal criteria airflow limitation (forced expiratory volume in
1 s (FEV1)/forced vital capacity (FVC) post-bronchodilation z-score <−1.645 on Global Lung
Function Initiative reference values (GLI2012)) or with GOLD fixed-limit criterion (FEV1/FVC
post-bronchodilation <0.70)
FEV1/FVC <0.70 FEV1/FVC <LLN
Subjects 80 55
GOLD grading
Mild (>80% predicted) 51.2 40.0
Moderate (50–80% predicted) 42.5 50.9
Moderately severe (30–50% predicted) 6.3 9.1
Severe (<30% predicted) 0.0 0.0
z-score-based grading
Mild (z-score >−2) 70.0 60.0
Moderate (z-score −2 to −2.5) 8.8 9.1
Moderately severe (z-score −2.5 to −3) 10.0 14.5
Severe (z-score −3 to −4) 11.3 16.4
Very severe (z-score <−4) 0.0 0.0
Data are presented as n or % of subjects with airflow limitation.
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the dependence of the FEV1/FVC ratio on a person’s height. Using a fixed-limit criterion can cause an
increasing level of overdiagnosis of airflow limitation with increasing height. Shorter subjects have normally
higher ratios and taller subjects have physiologically lower ratios [10]. In our study the rate of false positives
was not significantly higher in taller cohorts; however, of the false-positive cases, taller subjects had a
significantly higher FEV1/FVC ratio relative to reference values (figure 3). Unfortunately the absolute
number of obstructive individuals in our sample was too small for further analyses. Geographically, when
comparing populations, taller populations could thus have higher rates of false positives. Additionally, the
younger age cohorts in many countries are taller than their parents and grandparents. In Finland, the
average height of the population increased by 5 cm in both males and females from the 1970s to the 2010s
[51]. Thus, the level of overdiagnosis of airflow limitation using the FEV1/FVC fixed-limit criterion might
have an increasing trend as taller generations are reaching middle age.
Impact of overestimation with GOLD criteria
The GOLD criteria were introduced to facilitate the interpretation of spirometry, which was considered
difficult [1]. Generalisations can be useful, but they should not hinder correct diagnostics and treatment
choices. In moderately to severely reduced FEV1, the GOLD criterion functions well and correct
conclusions are reached even with this simplified “rule of thumb” [34]. These are also the patients that
should be considered for COPD medication and among whom the results from pharmaceutical trials,
using the inclusion criteria based on the GOLD criterion, are likely to be applicable to judge the costs and
benefits of treatment. It is, however, the potential for harm that should drive pulmonary professionals
towards change. All subjects benefit from the main treatment alternatives: quitting smoking, exercise,
vaccinations and eating a healthy diet to maintain normal weight. The opportunity for harm is twofold:
when pharmaceutical treatment is initiated to treat “reduced lung function” that is in fact normal and,
moreover, when other reasons for shortness of breath, dyspnoea and other respiratory symptoms are not
sought, when the patient is mislabelled as having COPD. There are no published studies that would have
proven any benefit of treating subjects with normal lung function (without asthma) with inhaled steroids
or long-acting bronchodilators, which on the contrary may have significant side-effects for the patients.
The level of overestimation of airflow limitation, determined here as 35% of the population, can result in
hugely excessive costs in terms of unnecessary pharmaceutical treatments.
Grading of degree of airflow limitation
We evaluated the grading system proposed by GOLD for applicability relative to z-score-based severity
grading. The GOLD limits of 80%, 50% and 30% are not based on actual variability of FEV1 in healthy
nonsmokers or subjects with COPD, but were originally chosen based on expert opinion as convenient limits
that are easy to remember [1, 34]. The GLI2012 reference values introduce individual z-scores, with increasing
variation of lung function with age taken into consideration with a separately modelled coefficient of variation
(S) [10]. Traditionally, a fixed limit of the fifth percentile, commonly 80% of predicted, has been considered as
the LLN for all ages [10]. The true fifth percentile varies with age and what commonly is 80% of predicted in
those 20–30 years old is more likely 65–75% in the older age categories [10]. Thus, the use of z-scores to
incorporate this variability gives a more accurate estimate of LLN, but also the degrees of reduced lung
function, as seen in figure 3 and table 3. The GOLD limits fail to identify differences in FEV1 levels. Use of
more accurate z-score-based grading of COPD could improve the grading of COPD and assessment of
treatment options, even though airflow limitation is just one of the phenotypes of COPD [52].
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FIGURE 4 Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative
reference values (GLI2012) [10] expressed as FEV1 % pred versus FEV1 z-score stratified by sex (males n=596;
females n=727). Reference values of 80% of predicted and z-score −2.0 are indicated by dotted lines.
ERJ Open Res 2016; 2: 00084-2015 | DOI: 10.1183/23120541.00084-2015 9
COPD | A. KAINU ET AL.
Limitations of the study
There is no golden standard for the true prevalence of airflow limitation in the general population. Among
healthy nonsmokers the recommended fifth percentile LLN should by definition identify 5% of subjects
with reduced values. In the absence of a gold standard, comparisons between different diagnostic limits are
relative. The population sample has a limited number of subjects with pathological airflow limitation
consistent with COPD to assess, which limits further analysis. However, we have shown that the GLI2012
values differentiate between subjects with airflow limitation consistent with COPD and can potentially give
severity grading of reduced ventilatory capacity more substance. Further studies on patient populations are
needed to evaluate the grading system more thoroughly. The GLI2012 limit of z-score −3 would seem to
correspond to the previous limit of 50% of predicted fairly well (figure 4). The low prevalence of airflow
limitation found in the general population in comparison with other studies (table 1) is notable especially
regarding various selection biases. However, compared with other Finnish studies from the same timespan
(e.g. the Health 2000 study [41]), the population prevalences of GOLD criteria airflow limitation and
smoking are similar. In addition, a nonresponder study was performed in Kemi, where the nonresponders
were found to be more often smoking young men, which did not significantly affect survey results [39].
Airflow limitation consistent with COPD is prevalent in subjects ⩾40 years old and there was no difference
in these age groups in terms of participation.
The GLI2012 reference values have been shown to underestimate lung volumes by 3–5% in the Finnish
population, thus further study using severity grading from locally derived reference equations [39] is
needed. Also in this study, the GLI2012 reference values would seem to underestimate lung volumes
(FEV1), thus underestimating the degree of COPD by spirometric criteria, especially in females (table 3 and
figure 4). The new Finnish reference values have been calculated with GAMLSS modelling similar to the
GLI2012 model [53]. Local data can bridge the gap between GLI2012 and the clinical patient evaluation.
However, this does not invalidate the use of GLI2012 reference values in international comparisons.
Instead, the local data should be evaluated with models compatible with the modelling approaches taken
with the Global Lung Function Initiative. The Global Lung Function Initiative has made software tools
available to calculate correction factors for divergent population samples and it is foreseen that the Global
Lung Function Initiative models will be further developed to incorporate new data in the future [10].
Conclusions
The GLI2012 reference values provide a uniform standard for the diagnosis of airflow limitation and
should be used in lieu of the current GOLD criteria. Clinicians should be aware of the overestimation of
airflow limitation and COPD resulting from the current widespread use of the fixed-limit GOLD criterion.
One-third of cases identified with airflow limitation using the GOLD criterion had normal spirometry
with GLI2012 reference values. Given the age distribution at the population level, this could result in
potentially over half of cases identified being false positives. Overestimation of airflow limitation consistent
with COPD in the middle aged and elderly can result in excessive pharmaceutical costs, side-effects of
drugs used to treat COPD, and under-recognition of other causes of dyspnoea, cough and sputum
production in the ageing population. We recommend the speedy recognition of GLI2012 as a uniform
definition of airflow limitation in epidemiological research to substitute the spirometric GOLD criterion in
the diagnosis of post-bronchodilation airflow limitation consistent with COPD.
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